Automated quantification of abnormalities associated with COVID-19 from chest computed tomography (CT) can help clinicians evaluate the disease and assess its severity and progression. This paper proposes measures of disease severity and a deep learning and deep reinforcement-based method to compute them.
INTRODUCTION
Coronavirus disease is an infectious disease affecting more than 900,000 patients worldwide as of April 1, 2020(1). The disease is caused by the severe-acute respiratory symptom Coronavirus 2 (SARS-Cov2) and has a high case fatality rate of up to 4% (2) with more than 45,000 deaths reported currently. Due to a high reproduction number and infectious nature of the disease, tools for rapid testing and evaluation are vital to track and mitigate the spread. Non-contrast Chest Computed Tomography (CT) has been useful to detect, quantify severity, and assess progression of the disease. We propose an automated system that can quantify the abnormalities most often seen in COVID-19, i.e., ground glass opacities and consolidations. The system will output regions of abnormality demarcated in a 3D CT scan and output two combined severity measures of the disease: (Percentage of Opacity, Percentage of High Opacity) and (Lung Severity Score, Lung High Opacity Score). The first measure (PO, PHO) indicates the overall disease spread relative to the volume of the lungs, while the second (LSS, LHOS) is a cumulative measure of the extent of involvement for each lung lobe (Fig. 1) . Given that high opacity abnormalities were shown to correlate with severe symptoms, both measures cover both the extent of disease and the presence of high opacities (3, 4) . The ability to determine the extent of disease and quantify the presence of high opacities provides valuable insight for prognosis prediction, risk prioritization, and therapy response (5) .
Background: CT imaging for COVID-19
COVID-19 is confirmed via a reverse transcription polymerase chain reaction (RT-PCR) (6) . However, the sensitivity of this test may be as low as 60-70% (7) and can cause false negatives in the first few days.
Moreover, there is currently a shortage of testing kits available which is contributing to undetected spread. Although the role of CT for diagnosis is currently being debated, two preliminary studies (8, 9) showed that Chest CT imaging of the lung provides improved sensitivity when compared to RT-PCR for patients suspected to have COVID-19. The primary features seen on a lung affected by COVID-19 are peripheral focal or multi-focal ground glass opacities, consolidation and crazy-paving patterns. Another study evaluated CT scans of patients tested positive for COVID-19 across 552 hospitals in China (4) . They found that 84.4% of patients exhibiting mild symptoms showed CT changes, whereas 94.6% of patients exhibiting severe symptoms showed CT changes. In a study of 121 patients, Bernheim et al showed that
CT changes correlated with disease severity, with increasing lung involvement and abnormalities as the disease progressed (10) . A recent radiologist performance study also points to preliminary evidence that radiologists can discriminate COVID-19 from other types of pneumonia (11) . The study showed that seven U.S. and Chinese radiologists were able to identify COVID-19 from other types of viral pneumonia with a median sensitivity of 73% and a median specificity of 93%. The studies so far have been performed on patients either suspected or confirmed to be tested positive of COVID-19, therefore it is too early to state that CT can be used as an effective diagnostic or screening tool for evaluation of COVID-19 in general population. However, most patients with COVID-19 exhibit CT abnormalities and the extent of these changes seem to correlate with disease severity. As a result, CT imaging is being adapted as a tool to evaluate COVID-19 in emergency rooms across the world, where other resources for testing are scarce.
MATERIALS AND METHODS

Datasets and Annotation
We used two different datasets in this work. The datasets were anonymized and retrospectively collected from multiple centers. The first, to develop and fine-tune lung and lobe segmentation and the second to develop the abnormality segmentation algorithm. The lung/lobe segmentation dataset has 8792 CT volumes. Complete details of the dataset are provided in Table 1. The abnormality   segmentation algorithm was trained on 613 CT volumes (see Table 2 ). Due to the evolving nature of the COVID-19 situation, and the limited availability of the data, we determined three groups of data that are useful for training and testing for the abnormality segmentation task: COVID-19 datasets, viral pneumonia datasets and other Interstitial Lung Diseases (ILDs). Note that parts of the statistical information were not available due to various levels of anonymization.
Lung and Lobe Segmentation
The algorithm generates lung and lobe segmentation mask on a given CT data set in four steps. First, multi-scale deep reinforcement learning (12) is used to robustly detect anatomical landmarks in a CT volume. The carina bifurcation and the sternum tip are used as landmarks with first and second preference respectively, to identify the lung region of interest (ROI). The size and the relative location of the lung ROI to the landmark are specified according to annotated data. Next, the lung ROI image is resampled to a 2mm isotropic volume and fed into a Deep Image-to-Image Network (DI2IN) (13) to generate the lung segmentation. Finally, the ROI segmentation mask is remapped to have the same dimension and the resolution as the input data. The DI2IN has been first trained on a large cohort of patients with various diseases, then fine-tuned with a cohort with abnormal patterns including ground glass opacities, consolidation, effusions, and masses, to improve the robustness of the lung segmentation over the infected areas.
COVID-19 Related Abnormality Segmentation
We formulate the segmentation of the COVID-19 related abnormality patterns as a semantic segmentation problem involving binary classes. A DenseUNet (14) with anisotropic kernels is trained to transfer a 3D Chest CT volume to a semantic segmentation mask of the same size. We define all voxels within the lungs that fully or partially contain ground glass opacity or consolidations as the positive voxels. The rest of the image areas within the lungs and the entire area outside the lungs are defined as negative. The network is trained as an end-to-end segmentation system. The 3D output segmentation is filtered by the lung segmentation as described above. The technical details of the network architecture and the training strategy are summarized in the supplementary material.
COVID-19 Severity Measures
The severity of COVID-19 in each subject is measured by the combined metrics (PO, PHO) and (LSS, LHOS) as defined below.
1) Percentage of Opacity (PO):
The Percentage of Opacity is calculated as the total percent volume of the lung parenchyma that is affected by disease:
2) Percentage of High Opacity (PHO):
The Percentage of High Opacity is calculated as the total percent volume of the lung parenchyma that is affected by severe disease i.e., high opacity regions including consolidation:
= 100 × ℎ ℎ
3) Lung Severity Score (LSS):
The Lung Severity Score is computed to measure the extent of lung involvement across each lobe as described by Bernheim et al (10) . For each lobe, the percentage of affected lobe is calculated and scored between 0-4.
• 0: lobe is not affected.
• 1: 1-25% of the lobe is affected.
• 2: 25-50% of the lobe is affected.
• 3: 50-75% of the lobe is affected.
• 4: 75-100% of the lobe is affected.
The scores for each of the 5 lobes are summed up to get the total LSS, resulting in a total score range from 0-20. 0 indicates that none of the lobes are involved and 20 indicates that all 5 lobes are severely affected.
4) Lung High Opacity Score (LHOS):
The Lung High Opacity Score is computed to measure the extent of abnormalities with severe disease. For each lobe, the percentage of high opacity is calculated and scored between 0-4.
• 0: lobe is not affected, or abnormalities do not have any consolidation.
• 1: 1-25% of the lobe has high opacity abnormalities.
• 2: 25-50% of the lobe has high opacity abnormalities.
• 3: 50-75% of the lobe has high opacity abnormalities.
• 4: 75-100% of the lobe has high opacity abnormalities.
The scores for each of the 5 lobes are summed up to get the total LHOS, resulting in a total score range from 0-20. 0 indicates that none of the lobes have a high opacity abnormality and 20 indicates that all 5 lobes are severely affected by high opacity consolidations.
RESULTS
Training of Lung and Lobe Segmentation
We used 8792 Chest CT images for training the 3D segmentation of lung and lobes. The detailed demographic and statistical information of training images can be found in Table 1 . The ground truth for each training and testing data set was generated by expert readers with a custom annotation tool. The readers could load the anonymized 3D CT series (volume), interact with the image (including 3 multi-planar reformatted images), draw and edit contours and mark regions with a specific label for each of the lung lobes that was pre-specified. The final mask was saved as a file together with the reference to the original anonymized CT series. The annotations were reviewed according to internal quality guidelines, that require at least one review for each annotation. Accordingly, each annotation was reviewed by a second, more experienced reader. The DI2IN has been first trained on a data set from 8087 patients (8006 for training, 81 for validation) without the prevalence of viral pneumonia, then it has been fine-tuned on another data set from 705 patients (645 for training, 60 for validation) with abnormality patterns including ground glass opacities, consolidation, effusions, masses, etc., to improve the robustness of the lung/lobe segmentation over the infected areas. It was finally tested on a data set from 100 patients, consisting of 50 COVID-19 and 50 controls (15) .
Training of Abnormality Segmentation
For the training of abnormality segmentation, we used a combination of COVID19, viral pneumonia, and other Interstitial Lung Diseases (ILDs) datasets, totaling 613 CT scans (160 COVID-19, 172 viral pneumonia, and 296 ILD). Atypical pneumonia datasets including SARS, MERS, and other viral pneumonia have a similar abnormalities as COVID-19 (16) and are used as reasonable proxies to complement the COVID-19 training dataset together with CT datasets that include other IDLs that present with GGO and consolidation. These datasets are used in the training dataset to learn the patterns relevant in COVID-19. The ground truth for each training data set was generated by an expert reader with a custom annotation tool. The reader could load the anonymized 3D CT series (volume), interact with the image (including 3 multi-planar reformatted images), draw and edit contours and mark regions with a specific label for the abnormalities related to COVID-19 that was pre-specified. The final mask was saved as a file together with the reference to the original anonymized CT series. The annotations were reviewed according to internal quality guidelines by a board-certified radiologist. For the testing set, both the initial annotation and final review was done by a board-certified radiologist. For testing, we used the same 100 datasets as for the lung and lobe segmentation, which includes 50 COVID-19 and 50 controls (15) .
Computation of Combined Measures of Disease Severity
From the predicted abnormality segmentation, we compute the two proposed combined measures of disease severity: (PO, PHO) and (LSS, LHOS) for the 100-test data set that consists of 50 COVID-19 and 50 controls. For computation of high-opacity regions, we use a threshold of -200 H.U., which was empirically determined.
We compute a Pearson correlation coefficient between each metric calculated on the predicted masks (abnormality, lung, and lobes) and ground truth masks (abnormality, lung, and lobes). We compute this statistic for both positives and negatives together, and for COVID-19 positive cases only. The latter computation is performed to show the linear correlation between the predicted and ground truth scores for patients with lung abnormalities only. We also compute the Kendall's rank correlation test for COVID-19 positive cases, which considers the distribution of scores across the range of the score. Figure   3 shows the scatter plot between ground truth and predicted metrics The Pearson coefficients for both positive and negative cases together are 0.98, p=5.5e-68 (PO); 0.98, p=1.85e-75 (PHO); 0.97, p= 4.16e-63 (LSS); and 0.97, p=6.15e-61 (LHOS). The detailed results of all statistics can be seen in Table 3 . All that all the markers for abnormalities greater than 0 fall below the line, indicating various levels of consolidation present. The closer a subject's marker is to the diagonal, the more consolidation there is in their lungs. In the right plot of Figure 4 , the diagonal indicates that LSS is equal to LHOS. A marker on the diagonal here indicates that all the lobes that are involved have high opacity. When a subject's marker falls below the diagonal, it means that either some lobes do not have high opacities or that they have less extent of high opacities. Figure 5 shows the qualitative results for four representative COVID19 positive cases along with their scores. For example, the upper left corner case results in (PO, PHO) = (61.6%, 17.5%). That means that 61.6% of the lung volume is affected by disease and 17.5% of the lung volume has high consolidation abnormalities.
DISCUSSION
In this work we proposed a method to automatically quantify regions with ground glass opacity and consolidation in Chest CT scans using state-of-the-art deep learning algorithms. The abnormalities detected by our system are the most common Chest CT findings in COVID-19. The system outputs the 3D contours of the CT abnormalities and computes two combined severity measures (Percentage of Opacity, Percentage of High Opacity) and (Lung Severity Score, Lung High Opacity Score).
Clinical value of our system
Automated characterization of disease can be extremely useful to facilitate rapid response in assessing the extent of lung infection and progression of the disease in patients exhibiting symptoms of COVID-19.
Evaluation of a Chest CT can be used to answer several questions in a clinical setting such as triage of a patient, diagnosis, assessment of severity and progression, and response to therapy. Recently, lung severity measures have been proposed for COVID-19 that demonstrate correlation to disease severity and progression (10, (17) (18) (19) (20) . Manual calculation of these scores produces a two-fold problem: either the affected regions are annotated precisely, which is a time-consuming process, or the affected regions are assessed subjectively, which translates into low reproducibility of the assessment. A precise automated measurement of lung severity scores will address both the speed and reproducibility problems.
The automatic computation of (PO, PHO) and (LSS, LHOS) as provided by our system is useful in several clinical scenarios:
• Severity assessment: An objective quantitative measure of severity is provided by (PO, PHO) and
(LSS, LHOS). This measure can be used in triage, to prioritize patients requiring hospital or ICU admittance, and to assess the prognosis of a patient.
• Progression assessment: In several instances, the patient might be imaged multiple times to assess disease progression or to assess response to drugs. In order to make these decisions, an objective metric or a score that can assess the extent of disease is vital. The (PO, PHO) and (LSS, LHOS) scores can be useful when evaluating a patient's response to a treatment or a drug and track the progression of the disease and estimate the stage of the disease in a patient. Such a tool could also be used in scientific research studies that are documenting the temporal radiological change of COVID-19 pneumonia.
• Early detection: Although the evidence is preliminary, the system could be used as an effective tool in conjunction with RT-PCR tests to increase overall sensitivity of COVID-19 detection, especially in scenarios where there are limited resources and a crunch for time.
An automated system that can perform this disease severity assessment can be of great use to hospitals that have a shortage of manpower combined with a high-volume of patients during the outbreak (5).
Technical Contributions
To our knowledge this is one of the first system to provide an automatic, efficient, and detailed evaluation of tomographic CT patterns associated with COVID-19. We also believe that this is the first system to propose and show how to automatically compute severity measures such as (PO, PHO) and
(LSS, LHOS) that characterize not only the extent of disease in the lungs, but also the extent of high opacity abnormalities, both globally and lobe-wise. This performance is facilitated by the experience of a multidisciplinary team (clinicians, machine learning experts, and engineers) including clinical knowledge and insight, annotation of ground truth, and multiple deep learning and deep reinforcement learning algorithms to solve robust landmark detection in Chest CT, 3D lung and lobe segmentation, and 3D segmentation of abnormalities associated with COVID-19.
Limitations
The system was trained with specific abnormalities that were relevant to COVID-19 such as ground glass capacities and consolidation. Presence of other abnormalities in or around the lung such as pleural effusion could produce challenges to the algorithm. In the future, the system will be trained comprehensively to account for abnormalities other than GGO and consolidation. The system produces a quantification of abnormalities in a lung CT scan only. It is hard to ascertain the diagnosis based on this information alone. In the future, we will evaluate the feasibility of distinguishing COVID-19 from other types of pneumonias and ILDs.
Disclaimer: The concepts and information presented in this paper are based on research results that are not commercially available
SUPPLEMENTAL INFORMATION
Abnormality Segmentation Network Architecture
The training images are firstly resampled to the resolution 1 × 1 × 3mm. The image intensity is clipped using the standard lung window with the width 1500 HU and level −600 HU before being normalized to We use the Jaccad index as the training loss function. The loss function L(p,y) between the probability prediction tensor p and the ground truth tensor y is only computed within the precomputed lung segmentation as where is the smoothing factor and · represents the tensor inner product operator. The loss function is optimized using Adabound (22) with an initial learning rate 0.001. cases and 50 controls. PO gives the extent of opacity and PHO gives the extent of the abnormality that has a high opacity, corresponding to consolidation regions. On the left, the diagonal line indicates PO and PHO are equal, i.e., that the abnormalities have 100% consolidation. The closer a marker is to the diagonal, the higher the relative percentage of consolidation in that subject. On the right, the diagonal indicates that all the lobes that are affected have a high percentage of consolidation as well. The points below the diagonal indicate that some of the lobes affected do not have as severe consolidation as the others. (see section COVID-19 Severity Metrics). Note that a small jitter (0.2%) is added for the purpose of visualization to represent overlapping points. 
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